Chugai Pharmaceutical boosted by Roche's Q1 sales, affirms guidance

Chugai Pharmaceutical (TSE: 4519) has reported a strong first quarter for 2025, fueled by robust sales performance from its strategic alliance partner, F. Hoffmann-La Roche. Roche's Q1 results included substantial contributions from Chugai, reinforcing the integrated nature of their operations. Chugai's revenue reached JPY 288.459 million, up 21.7% year-over-year, with Core operating profit surging 36.8% to JPY 136.651 million. Domestic sales remained steady, while international sales soared due to increased exports of Hemlibra and Actemra to Roche.